Holen Sie sich die Stockscreener-App
27.62
3.91%
1.04
Handel nachbörslich:
27.10
-0.52
-1.88%
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli’s New Approval (APLS) - Seeking Alpha
Signal strength of Apellis Pharmaceuticals Inc. stock in tech scannersJuly 2025 Summary & Daily Stock Momentum Reports - Newser
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Watch for Trend Continuation in Apellis Pharmaceuticals Inc. Next Week2025 Major Catalysts & Risk Controlled Swing Trade Alerts - beatles.ru
Apellis Pharmaceuticals (APLS) Surges 10.27% on FDA Approval Momentum and Strategic Deals - AInvest
FDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week - Insider Monkey
Apellis Pharmaceuticals' Stock Surges 27.70% This Week Following FDA Approval, Q2 2025 Financial Results, and Capped Royalty Purchase Agreements - AInvest
Published on: 2025-08-12 03:12:35 - beatles.ru
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $20 to $57 - 富途牛牛
11 Best Short-Term Stocks to Invest in - Insider Monkey
Apellis wins FDA label expansion for Empaveli in rare kidney disorders - MSN
Fierce Biotech Layoff Tracker 2025: Tune, Bicycle let go of 25% of staff - Fierce Biotech
Apellis Pharmaceuticals' Empaveli Faces Market Challenges and Physician Preferences - AInvest
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences - TipRanks
Apellis Pharmaceuticals (APLS) Sees Target Price Raised by Citig - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2025 Earnings Call Transcript - Insider Monkey
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS) and Akero Therapeutics (AKRO) - The Globe and Mail
Published on: 2025-08-04 22:37:11 - beatles.ru
Why Apellis Pharmaceuticals Shares Are Gaining Attention - TipRanks
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastInvest smarter with actionable stock recommendations - Jammu Links News
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug - MSN
Apellis’ EMPAVELI Approved by FDA for Rare Kidney Diseases - MSN
When is Apellis Pharmaceuticals Inc. stock expected to show significant growthBuild a portfolio with strong long-term growth - Jammu Links News
How many analysts rate Apellis Pharmaceuticals Inc. as a “Buy”Exceptional profit potential - Jammu Links News
What makes Apellis Pharmaceuticals Inc. stock price move sharplyDiscover undervalued stocks ready to soar - Jammu Links News
Is Apellis Pharmaceuticals Inc. a growth stock or a value stockFree Stock Movement Tracking - Jammu Links News
How strong is Apellis Pharmaceuticals Inc. company’s balance sheetBuild wealth steadily with proven investment techniques - Jammu Links News
How volatile is Apellis Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough growth with proven strategies - Jammu Links News
What analysts say about Apellis Pharmaceuticals Inc. stockConsistent triple-digit returns - Jammu Links News
What catalysts could drive Apellis Pharmaceuticals Inc. stock higher in 2025High-octane investment gains - Jammu Links News
What drives Apellis Pharmaceuticals Inc. stock priceCapitalize on market trends before they peak - Jammu Links News
What institutional investors are buying Apellis Pharmaceuticals Inc. stockFree Stock Movement Tracking - Jammu Links News
Why is Apellis Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock exclusive stock market forecasts - Jammu Links News
How does Apellis Pharmaceuticals Inc. generate profit in a changing economyUnlock powerful portfolio optimization tools - Jammu Links News
What are Apellis Pharmaceuticals Inc. company’s key revenue driversBuild a portfolio that stands the test of time - Jammu Links News
Apellis Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Apellis Pharmaceuticals: Navigating Q2 Earnings and Building a Complement-Driven Ophthalmology Powerhouse - AInvest
What are the latest earnings results for Apellis Pharmaceuticals Inc.Free Stock Target Finder For Fast Growth - jammulinksnews.com
Apellis Pharmaceuticals (APLS) Stock Forecast and Price Target 2025 - MarketBeat
Apellis Pharmaceuticals: The Picture Becomes Clearer (NASDAQ:APLS) - Seeking Alpha
Apellis Pharmaceuticals Surges 17.6% on Higher Price Target from Scotiabank - AInvest
Apellis (APLS) Price Target Raised as Market Stabilizes - GuruFocus
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $19 to $57 - 富途牛牛
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 E - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Surges 25% Yet Its Low P/S Is No Reason For Excitement - 富途牛牛
APLS: Cantor Fitzgerald Raises Price Target for Apellis Pharmace - GuruFocus
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say - MSN
Analyst Raymond James Lowers Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News - GuruFocus
Apellis: Raymond James Maintains Outperform, PT Down to $50 - AInvest
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):